DarioHealth (NASDAQ:DRIO) Lowered to Hold Rating by TD Cowen

TD Cowen downgraded shares of DarioHealth (NASDAQ:DRIO) from a buy rating to a hold rating in a research note released on Wednesday, MarketBeat Ratings reports. TD Cowen currently has $1.00 price target on the stock, down from their previous price target of $2.00.

DarioHealth Trading Down 5.0 %

Shares of DRIO opened at $0.66 on Wednesday. The stock’s fifty day simple moving average is $0.76 and its 200 day simple moving average is $0.90. DarioHealth has a twelve month low of $0.56 and a twelve month high of $2.60. The company has a current ratio of 1.57, a quick ratio of 1.32 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $22.34 million, a P/E ratio of -0.70 and a beta of 1.39.

DarioHealth (NASDAQ:DRIO) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $7.42 million during the quarter, compared to analyst estimates of $7.34 million. DarioHealth had a negative net margin of 205.62% and a negative return on equity of 72.16%. During the same period in the prior year, the firm earned ($0.49) earnings per share. On average, equities research analysts forecast that DarioHealth will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On DarioHealth

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd increased its holdings in DarioHealth by 81.4% in the 3rd quarter. XTX Topco Ltd now owns 29,455 shares of the company’s stock valued at $33,000 after purchasing an additional 13,219 shares in the last quarter. DLK Investment Management LLC boosted its position in shares of DarioHealth by 40.9% in the fourth quarter. DLK Investment Management LLC now owns 141,657 shares of the company’s stock worth $111,000 after buying an additional 41,107 shares during the period. Finally, Appian Way Asset Management LP grew its stake in shares of DarioHealth by 2.5% in the third quarter. Appian Way Asset Management LP now owns 1,410,870 shares of the company’s stock valued at $1,580,000 after buying an additional 34,990 shares in the last quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.